PNT News and Press, POINT Biopharma Global Inc. From 12/04/23

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023 PR Newswire INDIANAPOLIS , Dec. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and o...

2023-12-03 12:00:30 ET More on SPDR S&P Biotech ETF Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biopharma Bounce-Back: From Policy Pains To Profitable Plains Biotechs rally with gene editing stocks among nota...

2023-11-29 10:45:34 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – November 29, 2023 – USA News Group –  According to the European Cancer Information System (ECIS), new cancer cases and deaths are on the ri...

In Celebration of 25 Years of Giving, Double Match Offered for Employee Giving this Giving Tuesday NORTHAMPTON, MA and LONDON, UK / ACCESSWIRE / November 28, 2023 / Pentair plc (NYSE:PNR), a leader in helping the world sustainably move, improve and enjoy water, and the Pentair Foundation ann...

2023-11-24 13:00:31 ET More on the markets Broad Turn In Weekly Momentum Bodes Well For Stocks SPY: When Indicators Speak, The Year-End Rally Makes Little Sense 2024 U.S. Equities Outlook: Expect Bulls To Win This Round, Too Best stocks for when the 10-year T...

2023-11-17 07:21:14 ET More on Eli Lilly, POINT Biopharma Global, etc. Eli Lilly: Perfectly Priced Healthcare Giant POINT Biopharma Global: Why The Market Believes That A Second Bidder May Emerge Eli Lilly: Favorable Developments Continue Regarding Anti-Obesity Drug ...

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023 PR Newswire INDIANAPOLIS , Nov. 17, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and o...

2023-11-15 15:56:02 ET More on Point Biopharma Global POINT Biopharma Global: Why The Market Believes That A Second Bidder May Emerge Eli Lilly POINTs Toward Radiopharmaceutical Ambitions Eli Lilly extends expiration of tender offer to acquire Point Biopharma ...

Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma PR Newswire INDIANAPOLIS , Nov. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Nuclear Regulatory Commission ("NRC"...

2023-11-14 02:11:42 ET Summary POINT Biopharma Global is currently trading above Eli Lilly's tender offer price of $12.50. The reason for this is that the market believes that a second bidder may emerge, and the tea leaves support this possibility. BVF fund has refused to tend...